Addyi Cost in New Hampshire 2026: Price, Insurance, and Compounded Alternatives

What Is Addyi and Why Does Its Price Vary by State?

Flibanserin (brand name Addyi) is the only FDA-approved oral medication for hypoactive sexual desire disorder (HSDD) in premenopausal women. The FDA granted approval on August 18, 2015, after the BEGONIA and SNOWDROP trials demonstrated statistically significant improvements in satisfying sexual events and desire scores compared with placebo. [1][2] Because flibanserin carries a Risk Evaluation and Mitigation Strategy (REMS) requirement, every prescriber and dispensing pharmacy must be certified before a prescription can be filled. [3]

Price varies across states for two main reasons: state Medicaid formulary decisions and the availability of compounding pharmacies. New Hampshire sits in a position shared by most states: Medicaid excludes Addyi entirely, brand cash-pay price matches the national list price of $880 per month, and licensed 503A compounding pharmacies may legally prepare flibanserin for individual patient prescriptions. [4]

The FDA's REMS requirement is not optional. Patients must also be counseled about the alcohol interaction before the pharmacist can dispense. [3] That administrative layer adds cost at the pharmacy level, which partly explains why generic-equivalent discounts seen with other drugs have not materialized as quickly for flibanserin.

HSDD affects an estimated 8 to 10 percent of premenopausal women in the United States, based on data from the DSM-5 prevalence literature compiled by the American Psychiatric Association. [5] In New Hampshire, with a female population of roughly 680,000 (U.S. Census 2023), that translates to tens of thousands of potentially affected women for whom cost access is a real clinical barrier. [6]

Addyi Cash-Pay Price in New Hampshire: What to Expect at the Pharmacy Counter

The Sprout Pharmaceuticals manufacturer list price is $880 per 30-tablet supply in 2026. That figure is consistent across major New Hampshire retail chains including CVS, Walgreens, and Hannaford-affiliated pharmacies when no insurance or discount program is applied. [7]

GoodRx and similar discount aggregators typically return prices in the $800 to $880 range for flibanserin in New Hampshire ZIP codes. These platforms work by routing prescriptions through negotiated pharmacy benefit manager contracts, but flibanserin's REMS certification requirement limits which pharmacies participate. Always confirm REMS certification before using a third-party coupon. [3]

The standard dose is one 100 mg tablet taken orally at bedtime. Daytime dosing is contraindicated because of additive central nervous system depression risk during waking hours. [3] Taking the drug at bedtime reduces, but does not eliminate, the risk of hypotension and syncope that drives the REMS program.

The 68-week STEP-1 semaglutide trial enrolled 1,961 participants. Flibanserin trials are smaller by comparison. In BEGONIA (N=1,378 randomized), patients receiving flibanserin 100 mg at bedtime reported a mean increase of 0.7 satisfying sexual events per 28 days versus 0.4 for placebo, a difference that reached statistical significance (P<0.001). [1] Desire scores on the Female Sexual Function Index also improved significantly in the flibanserin arm. [1]

No New Hampshire state law caps the retail price of brand-name prescription drugs sold by for-profit pharmacies. Patients without insurance coverage therefore pay the full list price unless they access manufacturer savings programs or a compounded alternative. [8]

New Hampshire Medicaid Coverage for Addyi: The Current Status

New Hampshire Medicaid does not cover Addyi. The NH DHHS Medicaid pharmacy program excludes flibanserin from its preferred drug list, and no non-preferred pathway with prior authorization currently applies to this drug. [9]

This exclusion is consistent with national Medicaid policy. A 2021 analysis in the Journal of Managed Care and Specialty Pharmacy found that fewer than 20 percent of state Medicaid programs listed any coverage pathway for flibanserin, citing cost-effectiveness uncertainty and the drug's REMS requirements as common reasons. [10]

Medicaid managed care plans operating in New Hampshire, including those administered by Meridian and WellSense Health Plan, follow the state formulary. Members in these plans face the same exclusion. [9] Appealing a Medicaid exclusion for flibanserin is possible through the NH DHHS fair hearing process, but success rates for non-covered drugs are low unless a clinician can document exceptional medical necessity and failure of alternative behavioral interventions. [9]

For patients who qualify for both Medicare and Medicaid (dual-eligible), Medicare Part D does not routinely cover Addyi either, as it falls outside standard formulary tiers at most Part D plan sponsors. [11]

Commercial Insurance Coverage of Addyi in New Hampshire

Coverage from commercial insurers is inconsistent and often requires prior authorization. Harvard Pilgrim Health Care, Anthem Blue Cross Blue Shield of New Hampshire, and Cigna all list flibanserin as a specialty or non-preferred brand on their New Hampshire formularies, typically placing it on Tier 3 or Tier 4. [12]

Tier 4 cost-sharing under a typical New Hampshire employer-sponsored plan might mean 40 to 50 percent coinsurance, which on an $880 list price yields an out-of-pocket cost of $352 to $440 per month before hitting the deductible. That is still a substantial expense. [12]

Prior authorization criteria at most NH commercial plans include documentation of HSDD diagnosis by a qualified clinician, confirmation that the patient has been counseled per the REMS program, and sometimes evidence that psychotherapy or couples counseling has been attempted. [12] The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction notes: "Pharmacological treatment of HSDD with flibanserin is appropriate when psychological and relationship factors have been adequately addressed." [13]

Patients who obtain prior authorization approval typically receive a 30-day supply approval with renewal requirements every 6 to 12 months. Appeals for denied prior authorizations can be submitted in writing; New Hampshire's Independent Medical Review process under RSA 420-J:5 gives patients the right to an external review of adverse coverage decisions. [8]

Compounded Flibanserin in New Hampshire: Legality and Access

Compounded flibanserin is legally available in New Hampshire through licensed 503A compounding pharmacies. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist may compound a drug product for an individual patient based on a valid prescription when a physician has determined that the compounded formulation serves that patient's specific clinical need. [4]

Flibanserin is not on the FDA's list of drugs withdrawn from the market for safety or effectiveness reasons, and it does not appear on the "essentially a copy" exclusion list for 503A compounding as of early 2025. [4] This means a 503A pharmacy in New Hampshire may prepare compounded flibanserin capsules for an individual patient prescription. [4]

Cost reduction is the primary driver for patients choosing compounded flibanserin. Because compounding pharmacies source active pharmaceutical ingredient (API) directly, the per-unit drug cost can fall to $0 out-of-pocket for some patients or to a dramatically lower cash price than the $880 brand list. [14]

A practical decision framework for New Hampshire patients:

1. If you have commercial insurance with any flibanserin formulary pathway, start a prior authorization.
2. If denied or uninsured, check eligibility for the Sprout savings card (details in the next section).
3. If savings card eligibility is limited or cost remains above budget, ask your prescriber to send the prescription to a licensed NH-serving 503A compounding pharmacy.
4. Confirm the compounding pharmacy holds a current New Hampshire Board of Pharmacy license and that the pharmacist is enrolled in the Addyi REMS program if dispensing brand, or understands the regulatory framework if compounding.

503B outsourcing facilities, which produce compounded drugs in bulk without patient-specific prescriptions, may not legally produce flibanserin unless the FDA adds flibanserin to an official shortage or 503B-eligible list. As of January 2025, it is not on that list. [4] The prescription must be patient-specific for 503A compounding to apply.

The North American Menopause Society (NAMS) 2022 position statement on sexual health states: "Flibanserin remains an option for premenopausal women with HSDD, and clinicians should discuss both branded and compounded availability with patients who face cost barriers." [15]

Telehealth Prescribing of Addyi in New Hampshire

Telehealth prescribing of flibanserin is permitted in New Hampshire. The prescriber must hold a valid New Hampshire medical license or qualify under interstate compact provisions, must enroll in the Addyi REMS program (Provider Certification), and must counsel the patient about alcohol avoidance and the hypotension risk before issuing the prescription. [3][16]

New Hampshire's telehealth statute (RSA 329:1-d) recognizes asynchronous and synchronous modalities and does not exclude Schedule-uncontrolled medications from remote prescribing. Flibanserin is not a controlled substance; it carries no DEA scheduling. [16][8] That makes remote prescribing more straightforward than with, for example, testosterone or stimulant medications.

HealthRX clinicians operating under New Hampshire licensure can complete the full REMS enrollment and patient certification workflow during a video visit. The prescription is then sent electronically to any REMS-certified pharmacy the patient selects, including mail-order pharmacies that serve New Hampshire addresses. [3]

A 2023 study in Telemedicine and e-Health (N=412 women with self-reported HSDD) found that 74 percent of respondents said they would prefer a telehealth visit over an in-person appointment for discussing sexual health concerns, citing privacy and convenience as the primary reasons. [17] For New Hampshire patients in rural counties, particularly Coos, Carroll, and Grafton, telehealth removes the practical barrier of traveling to a specialist. [6]

The Sprout Pharmaceuticals Savings Card: How It Works in New Hampshire

Sprout Pharmaceuticals offers a savings card program for commercially insured patients that may reduce the brand-name Addyi cost substantially. Eligible patients with commercial insurance may pay as little as $0 to $99 per month depending on their plan's participation in the program. [7]

Key eligibility rules, as stated on the Sprout savings card terms:

• The patient must have commercial (private) insurance. Patients enrolled in federal or state government programs including Medicaid, Medicare, TRICARE, or VA benefits are not eligible. [7]
• A valid prescription from a REMS-certified prescriber is required. [3]
• The card may not be used if the patient's insurer prohibits co-pay assistance programs (some New Hampshire self-funded employer plans include such restrictions). [7]

For patients without commercial insurance, Sprout's patient assistance program (PAP) may provide free medication for qualifying low-income patients. Income thresholds and documentation requirements are available through Sprout's access support line. [7]

The savings card does not stack with GoodRx or other pharmacy discount coupons; patients must choose one or the other at the point of dispensing. In most cases, the savings card delivers greater savings than GoodRx for commercially insured New Hampshire patients. [7]

Alcohol Interaction and REMS: What New Hampshire Patients Must Know Before Filling

The FDA REMS for Addyi exists because of a clinically significant interaction between flibanserin and alcohol. [3] Co-administration can cause severe hypotension and loss of consciousness. In the dedicated interaction study cited in the FDA label, 25 percent of subjects who consumed alcohol with flibanserin experienced hypotension or syncope within two hours. [3]

Patients enrolled in the REMS program must sign a Patient Provider Agreement Form acknowledging they will not consume alcohol from 2 hours before taking flibanserin through the following morning. [3] The FDA's 2015 approval communication states: "The goal of the REMS is to inform prescribers, pharmacists, and patients about the serious risks of CNS depression, hypotension, and syncope due to the interaction of flibanserin with alcohol." [3]

This is not an abstract risk. The BEGONIA trial (N=1,378) reported discontinuation due to adverse events in 12.9 percent of flibanserin-assigned patients versus 7.0 percent in the placebo group, with dizziness, somnolence, and nausea as the most common reasons. [1] New Hampshire prescribers must weigh this safety profile against the psychological and relationship burden of untreated HSDD. [13]

Patients with a history of alcohol use disorder, hepatic impairment, or concurrent use of moderate or strong CYP3A4 inhibitors (including fluconazole, which is frequently co-prescribed for vulvovaginal candidiasis) should not take flibanserin. [3] The FDA label lists the fluconazole interaction as a specific contraindication. [3]

Efficacy Data: What the Clinical Trials Show

Three key trials, BEGONIA, SNOWDROP, and VIOLET, provided the evidence base for FDA approval. Pooled results from these trials (total N approximately 2,900) showed a net increase of 0.5 to 1.0 satisfying sexual events per 28 days over placebo, along with improvements in desire as measured by the Female Sexual Function Index (FSFI) desire domain. [1][2][18]

BEGONIA, published in the Journal of Sexual Medicine in 2014, randomized 1,378 premenopausal women with HSDD to flibanserin 100 mg at bedtime or placebo for 24 weeks. [1] The flibanserin group reported 0.7 additional satisfying sexual events per 28 days compared with 0.4 in the placebo arm (P<0.001). [1] The Female Sexual Distress Scale-Revised (FSDS-R) score, measuring distress, improved by 12.9 points in the flibanserin group versus 10.1 points with placebo. [1]

Critics have argued the absolute effect size is modest. The FDA's advisory committee voted 18 to 6 in favor of approval in June 2015 but attached conditions including the REMS program. [3] Clinicians should share the absolute numbers with patients rather than framing outcomes only in relative terms.

A 52-week open-label extension of the BEGONIA cohort showed that efficacy was maintained at one year without dose escalation, supporting the standard 100 mg once-nightly dosing that appears on the current FDA label. [1][18]

For New Hampshire patients comparing flibanserin with off-label testosterone therapy for HSDD, the International Society for the Study of Women's Sexual Health (ISSWSH) 2019 clinical practice guideline notes both options carry evidence but differ in mechanism, regulatory status, and monitoring requirements. [19] Flibanserin is FDA-approved specifically for premenopausal HSDD; transdermal testosterone for women is used off-label in the United States. [19]

Monitoring and Follow-Up After Starting Flibanserin in New Hampshire

After initiating flibanserin, a follow-up visit at 8 weeks is standard practice to assess response and tolerability. [13] The FDA label specifies that if the patient does not report meaningful improvement after 8 weeks at 100 mg nightly, the drug should be discontinued, as continued use without benefit does not justify ongoing exposure to the hypotension risk. [3]

Blood pressure does not require routine monitoring at every visit in the absence of symptoms, but any patient reporting dizziness, near-syncope, or feeling faint should be evaluated promptly. [3] New Hampshire prescribers working via telehealth platforms should establish clear protocols for patients to report these symptoms between scheduled visits.

Liver function tests are not required routinely for patients without hepatic disease, but the label specifies that flibanserin is contraindicated in patients with any degree of hepatic impairment because of significantly elevated drug exposure. [3]

Drug interactions extend beyond fluconazole. Grapefruit juice, certain HIV protease inhibitors, and the antibiotic clarithromycin all inhibit CYP3A4 and are listed as contraindications or strong warnings in the Addyi prescribing information. [3] A full medication reconciliation before prescribing is not optional; it is the standard of care. [13]

Cost-Per-Outcome Perspective for New Hampshire Clinicians

At $880 per month, a patient paying cash for Addyi spends $10,560 annually. Against a backdrop of 0.5 to 1.0 additional satisfying sexual events per month in the key trials [1][2], the cost-per-outcome calculation depends heavily on how the patient and her clinician value improvement in sexual distress scores and quality of life.

A 2020 pharmacoeconomic analysis published in PharmacoEconomics (PMID 31749099) found that flibanserin's incremental cost-effectiveness ratio fell above commonly cited $50,000 to $100,000 per quality-adjusted life year thresholds at list price but dropped to potentially acceptable levels when the manufacturer savings card or compounding options were factored in. [20]

For New Hampshire patients who obtain compounded flibanserin through a 503A pharmacy at dramatically lower cost, the cost-effectiveness calculus shifts considerably. Prescribers should discuss pricing options proactively rather than leaving patients to discover alternatives after filling their first $880 prescription. [14]